Relay Therapeutics(US:RLAY)2022-08-05 18:41Pipeline and Programs - Relay Therapeutics' pipeline includes RLY-4008 (selective FGFR2 inhibitor) with encouraging efficacy in FGFR2-fusion+ cholangiocarcinoma (CCA) without prior FGFRi [59] - RLY-2608 (PI3KαPAN inhibitor) is in development, with initial clinical data expected in the first half of 2023 [53, 137] - The company is also developing a selective CDK2 inhibitor, with clinical start expected in Q4 2023 or Q1 2024 [53, 157] - An ERα degrader program is underway, with a development candidate nomination expected in 2023 [53, 166] RLY-4008 (Selective FGFR2 Inhibitor) - A pivotal study is aligned with the FDA for FGFR2-fusion+ cholangiocarcinoma (CCA) without prior FGFRi, with a target enrollment of 100 patients [59, 98] - Preliminary data as of April 19, 2022, showed promising radiographic tumor regression in FGFRi-naïve cholangiocarcinoma QD patients [60, 92] - The company has enrolled 115 patients across 39 sites and 11 countries over 19 months for RLY-4008 [101] Financial Status - As of the end of Q2 2022, Relay Therapeutics had $838 million in cash, cash equivalents, and investments [53] - The company's current cash position is expected to fund the current operating plan into 2025 [53, 180]